|
|
| IANISKI,FRANCINE R.; RECH,VIRGINIA C.; NISHIHIRA,VIVIAN S.K.; ALVES,CATIANE B.; BALDISSERA,MATHEUS D.; WILHELM,ETHEL A.; LUCHESE,CRISTIANE. |
| ABSTRACT Considering that Alzheimer's disease is a prevalent neurodegenerative disease worldwide, we investigated the activities of three key kinases: creatine kinase, pyruvate kinase and adenylate kinase in the hippocampus and cerebral cortex in Alzheimer's disease model. Male adult Swiss mice received amyloid-β or saline. One day after, mice were treated with blank nanocapsules (17 ml/kg) or meloxicam-loaded nanocapsules (5 mg/kg) or free meloxicam (5 mg/kg). Treatments were performed on alternating days, until the end of the experimental protocol. In the fourteenth day, kinases activities were performed. Amyloid-β did not change the kinases activity in the hippocampus and cerebral cortex of mice. However, free meloxicam decrease the creatine kinase... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Alzheimer's disease; Nanoparticles; Meloxicam; Energetic metabolism; Phosphoryltransfer network. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652016000501829 |
| |
